Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders.

RNA-targeting therapeutics gene therapy neurological disorders programmable macromolecules

Journal

RNA (New York, N.Y.)
ISSN: 1469-9001
Titre abrégé: RNA
Pays: United States
ID NLM: 9509184

Informations de publication

Date de publication:
04 2023
Historique:
pubmed: 25 1 2023
medline: 22 3 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

Disruptions in RNA processing play critical roles in the pathogenesis of neurological diseases. In this Perspective, we discuss recent progress in the development of RNA-targeting therapeutic modalities. We focus on progress, limitations, and opportunities in a new generation of therapies engineered from RNA binding proteins and other endogenous RNA regulatory macromolecules to treat human neurological disorders.

Identifiants

pubmed: 36693761
pii: rna.079519.122
doi: 10.1261/rna.079519.122
pmc: PMC10019361
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

489-497

Subventions

Organisme : NINDS NIH HHS
ID : F32 NS112654
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG004659
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS103172
Pays : United States

Informations de copyright

© 2023 Morelli et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.

Références

Sci Transl Med. 2022 Jun 29;14(651):eabn2375
pubmed: 35767654
Nat Neurosci. 2013 Apr;16(4):499-506
pubmed: 23416452
Nat Methods. 2019 Mar;16(3):239-242
pubmed: 30737497
J Neurosci. 2010 Jan 13;30(2):639-49
pubmed: 20071528
Nat Rev Drug Discov. 2021 Jun;20(6):412-413
pubmed: 34012000
Mol Cell. 2018 Mar 1;69(5):893-905.e7
pubmed: 29499139
Hum Gene Ther. 2016 Jul;27(7):478-96
pubmed: 27267688
Nat Rev Cancer. 2011 Jan;11(1):59-67
pubmed: 21160526
Nat Rev Neurosci. 2007 Nov;8(11):819-31
pubmed: 17895907
N Engl J Med. 2018 Feb 15;378(7):625-635
pubmed: 29443664
Science. 2003 Oct 31;302(5646):819-22
pubmed: 14593166
Elife. 2018 Jan 05;7:
pubmed: 29303478
Nat Rev Mol Cell Biol. 2017 Jul;18(7):437-451
pubmed: 28488700
Science. 2009 Feb 27;323(5918):1208-1211
pubmed: 19251628
Nat Rev Drug Discov. 2010 Jan;9(1):57-67
pubmed: 20043028
Science. 2016 May 20;352(6288):982-6
pubmed: 27174676
J Clin Med. 2020 Jun 26;9(6):
pubmed: 32604776
Mol Cell Neurosci. 2013 Sep;56:406-19
pubmed: 23280309
Science. 2016 Aug 5;353(6299):aaf5573
pubmed: 27256883
Sci Adv. 2022 Jan 21;8(3):eabk2485
pubmed: 35044815
Expert Opin Biol Ther. 2015 Jul;15(7):1023-48
pubmed: 26017628
Cell. 2016 Apr 7;165(2):488-96
pubmed: 26997482
Signal Transduct Target Ther. 2021 Feb 21;6(1):74
pubmed: 33611339
Genes (Basel). 2017 Jan 26;8(2):
pubmed: 28134780
Mol Cell. 2018 Mar 1;69(5):906-914.e4
pubmed: 29456189
Lancet. 2011 Aug 13;378(9791):595-605
pubmed: 21784508
Nat Biotechnol. 2009 Jun;27(6):549-55
pubmed: 19465925
J Gene Med. 2021 Apr;23(4):e3321
pubmed: 33590603
Trends Neurosci. 2015 Apr;38(4):226-36
pubmed: 25765321
N Engl J Med. 2019 Oct 24;381(17):1644-1652
pubmed: 31597037
Nature. 2014 Dec 11;516(7530):263-6
pubmed: 25274302
Sci Adv. 2022 Sep 23;8(38):eabn4704
pubmed: 36129972
Cell Rep. 2022 Aug 16;40(7):111226
pubmed: 35977479
Front Immunol. 2021 Mar 17;12:658399
pubmed: 33815421
Mol Cell. 2017 Feb 16;65(4):618-630.e7
pubmed: 28065598
Mol Ther. 2009 Jul;17(7):1234-40
pubmed: 19455105
Genes Cells. 2019 Dec;24(12):827-835
pubmed: 31637814
Nat Biotechnol. 2019 Feb;37(2):133-138
pubmed: 30692694
Cell Rep. 2020 Nov 3;33(5):108350
pubmed: 33147453
Cell. 2016 Aug 25;166(5):1147-1162.e15
pubmed: 27565344
Dis Model Mech. 2017 May 1;10(5):509-518
pubmed: 28468937
J Neurochem. 2018 Oct;147(2):137-152
pubmed: 29873074
Front Neurosci. 2020 Feb 28;14:98
pubmed: 32184705
Cell. 2019 Jun 27;178(1):122-134.e12
pubmed: 31230714
Mol Ther. 2009 Jan;17(1):169-75
pubmed: 19002161
ACS Chem Neurosci. 2019 May 15;10(5):2355-2363
pubmed: 30835997
Nat Rev Neurol. 2018 Oct;14(10):570
pubmed: 30158559
Nat Commun. 2022 Mar 2;13(1):1125
pubmed: 35236841
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
Nat Biotechnol. 2020 Dec;38(12):1431-1440
pubmed: 32601430
Science. 2017 Nov 24;358(6366):1019-1027
pubmed: 29070703
Cell. 2011 Dec 23;147(7):1601-14
pubmed: 22196734
Nat Med. 2022 Jul;28(7):1372-1376
pubmed: 35668177
P T. 2014 Feb;39(2):119-22
pubmed: 24669178
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21441581
EMBO J. 2020 Nov 16;39(22):e104741
pubmed: 33058229
Nat Commun. 2016 Apr 04;7:11168
pubmed: 27041075
Elife. 2014;3:e01201
pubmed: 24448406
Nat Rev Genet. 2022 May;23(5):265-280
pubmed: 34983972
Methods. 2022 Sep;205:140-148
pubmed: 35764245
Nat Rev Genet. 2018 Dec;19(12):770-788
pubmed: 30323312
Crit Rev Biochem Mol Biol. 2021 Feb;56(1):31-53
pubmed: 33172304
Genome Res. 2011 Oct;21(10):1572-82
pubmed: 21846794
Nat Biomed Eng. 2021 Feb;5(2):157-168
pubmed: 32929188
RNA. 2003 Mar;9(3):309-18
pubmed: 12592005
Annu Rev Pharmacol Toxicol. 2010;50:259-93
pubmed: 20055705
BioDrugs. 2022 Mar;36(2):105-119
pubmed: 35254632
Nat Commun. 2021 Aug 24;12(1):5107
pubmed: 34429425
Neuron. 2019 Apr 17;102(2):294-320
pubmed: 30998900
RNA Biol. 2022 Jan;19(1):452-467
pubmed: 35352626
Cell. 2017 Aug 24;170(5):899-912.e10
pubmed: 28803727
Science. 2019 Jul 26;365(6451):382-386
pubmed: 31296651
Nat Rev Neurosci. 2016 May;17(5):265-81
pubmed: 27094079
Nat Biotechnol. 2012 Oct;30(10):920-3
pubmed: 23051805
Nat Neurosci. 2023 Jan;26(1):27-38
pubmed: 36510111
Mol Neurodegener. 2018 Oct 4;13(1):52
pubmed: 30286791
Nucleic Acids Res. 2016 Mar 18;44(5):2093-109
pubmed: 26553810
Cell. 2018 Apr 19;173(3):665-676.e14
pubmed: 29551272
Nat Biotechnol. 2019 Sep;37(9):1059-1069
pubmed: 31308540
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Nucleic Acids Res. 2022 Jun 24;50(11):e65
pubmed: 35244715
Cell Rep. 2019 Oct 8;29(2):301-316.e10
pubmed: 31597093
Am J Hum Genet. 2015 Jan 8;96(1):93-103
pubmed: 25557785
J Exp Biol. 2015 Jun;218(Pt 12):1812-21
pubmed: 26085659

Auteurs

Kathryn H Morelli (KH)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA.
Stem Cell Program, University of California San Diego, La Jolla, California 92093, USA.
Institute for Genomic Medicine, University of California San Diego, La Jolla, California 92039, USA.

Aaron A Smargon (AA)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA.
Stem Cell Program, University of California San Diego, La Jolla, California 92093, USA.
Institute for Genomic Medicine, University of California San Diego, La Jolla, California 92039, USA.

Gene W Yeo (GW)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA geneyeo@ucsd.edu.
Stem Cell Program, University of California San Diego, La Jolla, California 92093, USA.
Institute for Genomic Medicine, University of California San Diego, La Jolla, California 92039, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH